Supportive Care in the Treatment of Lower-Risk Myelodysplastic Syndromes

MDS: Introduction

2016 WHO Classification of Myeloid Neoplasms

Discrepancy in Diagnosis of MDS Between Treatment Centers

IPSS and IPSS-R

MD Anderson Model of Prognosis for Patients With LR MDS

CHIP

Case Study: Discussion

Supportive Care Asymptomatic Patients

Low-Dose Decitabine vs Low-Dose Azacitidine in LR/Int-1-Risk MDS

Does Early Intervention Help Patients with LR MDS?

Low-Dose Decitabine vs Low-Dose Azacitidine in LR/Int-1-Risk MDS

MD Anderson Model of Prognosis for Patients With LR MDS

NCCN 2017 LR/Int-1-Risk MDS With Symptomatic Anemia

Impact of Comorbidities by ACE-27 in the IPSS-R for MDS

Cytogenetic Groups of MDS

Goals of Therapy for LR MDS

Predictive Model for Response to Treatment With EPO + G-CSF

TELESTO Deferasirox in LR/Int-1 MDS With Transfusional Iron Overload

MDS-002/003 Lenalidomide in MDS

Lenalidomide vs Placebo in RBC Transfusion-Dependent LR MDS

Low-Dose HMAs in LR MDS

QUAZAR Azacitidine and BSC vs Placebo and BSC

Ongoing Clinical Trials in LR MDS

Thrombocytopenia in MDS

Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)